Management of KRAS-Mutated Non–Small Cell Lung Cancer

Abstract: Kirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non–small cell lung cancer (NSCLC), where mutations are present […]

Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy

H&O Which patients with early-stage non–small cell lung cancer (NSCLC) are eligible for surgical resection? HW We perform surgical resection in nearly all patients with stage […]

Neoadjuvant Immunotherapy in Resectable Non–Small Cell Lung Cancer

Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients […]

Ongoing Progress in BRAF-Mutated Non–Small Cell Lung Cancer

Abstract: Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non–small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated […]

Radiation Therapy and Immunotherapy in Locally Advanced NSCLC

H&O What is standard treatment in locally advanced non–small cell lung cancer (NSCLC)? PL Standard treatment in locally advanced NSCLC used to be 6 weeks of […]

Hem/Onc News

Entrectinib Approved for NTRK Fusion–Positive Solid Tumors and ROS1-Rearranged Non–Small Cell Lung Cancer On August 15, the US Food and Drug Administration (FDA) granted approval to […]

Hem/Onc News

Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]

ALK Inhibitors in Non–Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?

H&O Which patients with non–small cell lung cancer (NSCLC) are candidates for treatment with crizotinib? AS Crizotinib (Xalkori, Pfizer) is a multitargeted tyrosine kinase inhibitor […]

The Next Frontier in Non–Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade

Abstract: Immune checkpoint blockade (ICB), which harnesses the body’s immune system to recognize and kill cancer cells, has transformed the management landscape for patients with […]